MYX mayne pharma group limited

Ann: Mayne Pharma investor presentation to Goldmans conference, page-2

  1. 39 Posts.
    lightbulb Created with Sketch. 3

    Some good stuff in there and shows how close some new products are to FDA approval.

    What I particularly liked was the $40M+ spent on R&D for 2018.

    That's what I want from MYX - a company that is not standing still and is looking to grow.

    Yes they have been hit by a perfect storm with taking on Teva products as pricing was deflating, however, this will pass in time and recover.

    Then when it does I can take my shares out of the bottom drawer and look at them again.

    All this useless dribble about forward looking statements is just that dribble.

    In an uncertain environment that is not in your control you can't give forward guidance - if you do and get it wrong then you will be slaughtered.

    I would rather a company I am invested in to surprise to the upside not the other way (similar to MBL)

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$5.25
Change
-0.150(2.78%)
Mkt cap ! $426.5M
Open High Low Value Volume
$5.35 $5.41 $5.19 $1.239M 231.7K

Buyers (Bids)

No. Vol. Price($)
1 1000 $5.17
 

Sellers (Offers)

Price($) Vol. No.
$5.36 1000 1
View Market Depth
Last trade - 16.11pm 25/07/2025 (20 minute delay) ?
MYX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.